Press Release: Chondrial Therapeutics : Chondrial Therapeutics Announces Dosing of First Patients in Phase 1 Clinical Program of CTI-1601 for Treatment of Friedreich's Ataxia

CTI-1601 granted Rare Pediatric Disease Designation and Fast Track Designation by U.S. FDACTI-1601 granted Rare Pediatric Disease Designation and Fast Track Designation by U.S. FDA